News & Videos - MONOPAR THERAPEUTICS INC. - English - Page 2

WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a presentation. SNMMI 2024, held in...

WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that it has filed a provisional patent application pertaining to the recent advancements and optimizations Monopar has achieved with its MNPR-101 radiopharmaceutical program. The provisional patent titled “Antibody Radioisotope Constructs” that was filed with the United States...

WILMETTE, Ill., April 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) is now active and recruiting patients with advanced cancers. The antibody MNPR-101 targets the urokinase plasminogen activator receptor (uPAR),...

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments. Recent Developments Novel MNPR-101 Radiopharmaceutical Program targeting uPAR – Phase 1 dosimetry clinical trial to commence in the coming weeks MNPR-101-Zr Phase 1 dosimetry clinical trial has...

WILMETTE, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced positive preclinical imaging data of a therapeutic radioisotope bound to its proprietary uPAR (urokinase plasminogen activator receptor) targeting agent MNPR-101. The data clearly demonstrate highly preferential uptake in the tumor. This is an extension of the tumor imaging and...

WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that the internationally recognized radiopharmaceutical physician, Professor Rodney Hicks, will be the lead investigator for Monopar’s MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced cancer patients. Professor Hicks will enroll patients at the Melbourne Theranostic...

WILMETTE, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced promising preclinical imaging and therapeutic efficacy data for its MNPR-101 radiopharmaceutical program. This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative...

WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr. The MNPR-101-Zr Phase 1 dosimetry clinical trial will enroll patients with advanced cancers and will utilize positron...

WILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced third quarter 2023 financial results and summarized recent developments. Recent Developments MNPR - 101 for Radiopharmaceutical Use – First-in-Human Study to Start Potentially As Early As December of This Year Monopar continues to advance its MNPR-101...

WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will present data from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS) later today at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting,...

WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar’s Chief Operating Officer, will present at the Roth MKM 2023 Healthcare Opportunities Conference. Presentation Details: Date: October 12, 2023 Time: 12:15 p.m. (ET) Location: The Yale Club, New York City, New York...

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 25 th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 11, 2023 at 7:00 a.m. ET. In person one-on-one meetings will...

Camsirubicin Phase 1b Trial Currently at 5th Dose­-Level (650 mg/m 2 ), Generating Encouraging Results MNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-­stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced second quarter 2023 financial results and summarized recent developments. Recent...

WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Both patients treated to date at the 650 mg/m 2 dose level have experienced tumor size reductions – of 18% and 20% respectively –...

WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced a collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to evaluate radiopharmaceutical versions of MNPR-101 in several aggressive cancers. MNPR-101 is a novel, first-in-class humanized monoclonal antibody to the urokinase...

WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a panel discussion at the “Radiopharma Forum by the Lake” on Monday June 26, 2023, at 6:15pm CT at the Chicago Club. “We are excited to be a part of this event, which is bringing together...

WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a one-on-one fireside chat with Jason McCarthy, PhD, Senior Managing Director of Equity Research, at the Maxim Group’s Healthcare Virtual Conference on Tuesday June 20, 2023 at 1:30pm ET. Fireside...

Patient in 520 mg/m 2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m 2 cohort achieved stable disease WILMETTE, Ill., June 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced an update from its currently enrolling multi-center open-label Phase 1b clinical trial of...

WILMETTE, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical­stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2023 financial results and summarized recent developments. Recent Developments Camsirubicin – Phase 1b Dose­Escalation Trial, Currently Enrolling Fifth Dose­Level Cohort Phase 1b data...

WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week. Presentation Details: Date: April 3, 2023 Time: 1:00 – 1:30 pm Location: Jefferies...